Effect of anti-S phase agents on human chromosomes

抗S期药物对人类染色体的影响

基本信息

  • 批准号:
    8436839
  • 负责人:
  • 金额:
    $ 32.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-02-01 至 2018-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Anti-S phase agents like doxorubicin, gemcitabine, cytarabine and hydroxyurea are in extensive use for the treatment of cancers and of hematological diseases such as essential thrombocytopenia, polycythemia vera and sickle cell anemia. All these agents are believed to cause replication fork stalling leading to activation of checkpoint pathways that inhibit cell proliferation. Yet, not much is known about how these inhibitors inhibit the origins of replication, of the sites/DNA lesions responsible for checkpoint activation and of the effect of these lesions on chromosome structure or gene expression. In addition, many of these agents are known to affect gene expression by unknown mechanisms. For example, hydroxyurea has been used in sickle cell anemia because it increases the expression of fetal hemoglobin and decreases the expression of cell-surface adhesion molecules. We have recently published genomic approaches to study time of replication, origins of replication and effects of anti-S phase agents on the replication origins in human cells We have discovered that two anti-S phase agents used for therapy lead to the firing of clustered neo-origins, leading to a high density of stalled replication forks at defined sites in the genome. In this proposal we plan to determine whether this is a general feature of other anti-S phase agents, whether the sites where these clustered neo-origins occur are the same in different cell lines or whether the sites change when cells are exposed to these agents in all parts of the S phase. We will investigate whether the high density of stalled replication forks at clustered neo-origins make these sites of the genome susceptible to double-strand breaks (DSB) and chromosomal rearrangements. We will examine whether the disturbed state of the chromatin due to the high density of clustered neo-origins leads to suppression of gene expression. Finally, we will examine which, where and in what order checkpoint activators and DNA repair proteins are recruited to the stalled replication forks created by anti-S phase agents.
说明(申请人提供):阿霉素、吉西他滨、阿糖胞苷和羟基脲等抗S相药广泛用于癌症和血液病的治疗,如原发性血小板减少症、真性红细胞增多症和镰状细胞性贫血。所有这些药物都被认为会导致复制分叉停滞,导致抑制细胞增殖的检查点通路的激活。然而,关于这些抑制剂如何抑制复制的起源,负责检查点激活的部位/DNA损伤,以及这些损伤对染色体结构或基因表达的影响,人们还知之甚少。此外,已知其中许多药物通过未知的机制影响基因表达。例如,羟基尿素已被用于治疗镰状细胞性贫血,因为它增加了胎儿血红蛋白的表达,降低了细胞表面黏附分子的表达。我们最近发表了研究复制时间、复制起源和抗S相剂对人类细胞复制起始点影响的基因组方法。我们发现,用于治疗的两种抗S相剂导致聚集的新起始点的激发,导致在基因组中指定位置的高密度停滞的复制叉子。 在这项建议中,我们计划确定这是否是其他抗S期药物的一般特征,这些聚集的新起点在不同细胞系中出现的位置是否相同,或者当细胞暴露于这些药物时,S期所有部分的细胞是否发生改变。我们将调查在聚集的新起始点的高密度停滞的复制叉子是否使基因组的这些位置容易受到双链断裂(DSB)和染色体重排的影响。我们将检查由于聚集的新起源的高密度而引起的染色质的紊乱状态是否导致基因表达的抑制。最后,我们将研究哪些检查点激活物和dna修复蛋白被招募到由抗S相剂产生的停滞的复制叉中,在哪里,以什么顺序被招募。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anindya Dutta其他文献

Anindya Dutta的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anindya Dutta', 18)}}的其他基金

Involvement of Noncanonical Short RNAs in gene repression through the RNA-induced-silencing complex
非规范短 RNA 通过 RNA 诱导沉默复合物参与基因抑制
  • 批准号:
    10701797
  • 财政年份:
    2022
  • 资助金额:
    $ 32.79万
  • 项目类别:
Studies on ORC and double strand DNA break repair
ORC与双链DNA断裂修复的研究
  • 批准号:
    10377840
  • 财政年份:
    2021
  • 资助金额:
    $ 32.79万
  • 项目类别:
Studies on ORC and double strand DNA break repair
ORC与双链DNA断裂修复的研究
  • 批准号:
    10555198
  • 财政年份:
    2021
  • 资助金额:
    $ 32.79万
  • 项目类别:
Studies on ORC and double strand DNA break repair
ORC与双链DNA断裂修复的研究
  • 批准号:
    10328884
  • 财政年份:
    2021
  • 资助金额:
    $ 32.79万
  • 项目类别:
Mechanism of action of an lncRNA for directing muscle differentiation
lncRNA指导肌肉分化的作用机制
  • 批准号:
    10396900
  • 财政年份:
    2016
  • 资助金额:
    $ 32.79万
  • 项目类别:
Mechanism of action of an lncRNA for directing muscle differentiation
lncRNA指导肌肉分化的作用机制
  • 批准号:
    9914219
  • 财政年份:
    2016
  • 资助金额:
    $ 32.79万
  • 项目类别:
Effect of anti-S phase agents on human chromosomes
抗S期药物对人类染色体的影响
  • 批准号:
    8608500
  • 财政年份:
    2013
  • 资助金额:
    $ 32.79万
  • 项目类别:
Effect of anti-S phase agents on human chromosomes
抗S期药物对人类染色体的影响
  • 批准号:
    8997926
  • 财政年份:
    2013
  • 资助金额:
    $ 32.79万
  • 项目类别:
Androgen and MicroRNAs in Prostate Cancer
前列腺癌中的雄激素和 MicroRNA
  • 批准号:
    8038178
  • 财政年份:
    2011
  • 资助金额:
    $ 32.79万
  • 项目类别:
MicroRNAs in differentiation of muscle
MicroRNA在肌肉分化中的作用
  • 批准号:
    7883986
  • 财政年份:
    2009
  • 资助金额:
    $ 32.79万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.79万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了